#Realworlddata

[the-most-humble-blog]

💀 **REBLOG and Screenshot this before it mysteriously violates “community guidelines”**

🎥 Flashback Sequence:

Laken Riley. 22. Nursing student. Jogging on campus. Unarmed. Unaware. Unprepared.

José Ibarra. Illegal immigrant. Arrested for theft. Released. Still here. Why?

Because some activist in a city council meeting didn’t want to look racist on Twitter.

If Laken Riley had shoplifted in a foreign country, she’d be in jail. But when he shoplifted here, we gave him a second chance. That second chance cost her her life.

🧊 Enter: The Laken Riley Act

Signed January 29, 2025, by Trump (47). First act of the new term. Why? Because no one else had the spine to make murder prevention bipartisan.

📜 WHAT IT DOES:

✔️ Mandatory ICE detainment for illegals who commit:

Theft

Shoplifting

Assaulting police

Causing bodily harm or death

✔️ Allows states to sue DHS if policy failure leads to blood on the ground ✔️ Breaks sanctuary city protection shell ✔️ Backed by the Riley family, who were in the room when it passed

CHECKLIST FOR THE TRAGICALLY DELUDED:

🔲 Think ICE is evil 🔲 Think deportation is mean 🔲 Think everyone deserves another chance 🔲 Think borders are just lines 🔲 Think the system’s the problem

Now add one more box:

☑️ Think none of this will affect you—until it does.

🧠 Reblog if you’re done pretending chaos is compassion 🛡️ Follow if you’re sick of being told you’re heartless for valuing order 🔁 Comment if you think murder shouldn’t be a prerequisite for policy change 💀 Screenshot this before it mysteriously violates “community guidelines”

[segmed]

Unlocking The Power of Real World Imaging Datasets in R&D - Clinical Trials

Discover how Real-World Imaging Datasets (RWiD) are transforming clinical trials—enhancing patient selection, optimizing trial design, and accelerating evidence generation. Our latest blog explores how RWiD improves efficiency, reduces costs, and integrates AI/ML for groundbreaking insights in R&D. Read now to see how imaging is shaping the future of clinical trials!

[healtharkinsightss]

[anandshivam2411]

No Experience? No Problem! Build a Data Science Portfolio that Shines

Building a data science portfolio without formal job experience is achievable and can set you apart in a competitive field. Here’s a guide to crafting a portfolio that showcases your skills and passion effectively.

Start with Personal Projects on topics that genuinely interest you. Use public datasets to practice your analytical abilities, and don’t hesitate to experiment. This shows your initiative and problem-solving approach. Kaggle Competitions are also excellent for gaining experience and developing hands-on skills. Competing with other data enthusiasts, you’ll sharpen your techniques and add valuable projects to your portfolio.

Having a GitHub Repository is essential; it acts as a digital portfolio of your work, allowing potential employers to see your coding style and solutions firsthand. Complement your projects by Blogging about them. Write articles that explain your process, challenges, and insights — this is an excellent way to demonstrate your understanding and communicate complex concepts.

Collaboration is another vital aspect. Teaming up with others on data science projects or online forums allows you to learn new skills, gain insights, and create a well-rounded portfolio. Completing Online Courses and sharing their projects can also add credibility, especially when you apply concepts to real-world datasets, reinforcing your ability to analyze relevant topics.

Include Capstone Projects from bootcamps or advanced courses; these projects are structured to simulate actual industry problems and showcase your readiness for professional challenges. In your portfolio, emphasize your Problem-Solving Focus — how you approached each project analytically and your findings. And don’t forget Presentation Skills: ensure your portfolio is visually engaging, easy to navigate, and organized.

This masterclass provides guidance on each step, giving you the skills and confidence to build a portfolio that reflects your strengths and captures the attention of future employers.

[yashmedica]

Big Data in Healthcare: Transforming Medicine with Federated Learning and Real-World Data

Big Data in Healthcare – Revolutionizing Medicine with Federated Learning The healthcare industry is swimming in a sea of data. Electronic health records, medical imaging, genomic data – the volume, variety, and velocity of this information is immense. This is where Big Data in Healthcare comes in, offering the potential to transform how we diagnose, treat, and prevent diseases. One exciting…

[markethighs]

Title: “GetGrass: Unleashing the Power of Community Bandwidth for Decentralized Data”

Description: Welcome to the world of GetGrass, where blockchain intersects with real-world data! 🌐🌿 In this video, we dive into the revolutionary concept of GetGrass—a self-sustaining ecosystem fueled by the collective bandwidth of its community members. Discover how GetGrass is reshaping data oracles and empowering decentralized applications across the blockchain space. 🚀

Hashtags: #GetGrass #DecentralizedData #BlockchainRevolution #CommunityBandwidth #RealWorldData #CryptoInnovation

 Tags:

GetGrass, Decentralized Data, Blockchain, Community Bandwidth, Real-World Data, Crypto, Solana, Layer 2 Scaling, GRASS Tokens, Blockchain Revolution, Data Oracles, IoT Gadgets, AI Applications, Passive Earnings, Greener Future, Global Network, Crypto Innovation, Real-World Connectivity, Community Participation

[mikyit]

Real-world data 👀 (#RWD) and real-world evidence 🔍 (#RWE) are playing an increasing role in health care decisions. _______ FDA 🏦 uses #RWD and #RWE to monitor postmarket #safety and #AdverseEvents and to make #regulatory decisions. _______ The #healthcare #community 👨‍⚕️ is using these data to support coverage decisions and to develop guidelines and decision support tools for use in clinical practice. _______ #Medical product developers are using #RWD and #RWE to support clinical trial designs (e.g., large simple trials, pragmatic #ClinicalTrials) and observational studies 🔬 to generate innovative, new #treatment 💉 approaches.

[researchswatistuff]

Real-world Data Market Worth $2 billion by 2029

Meticulous Research®—A leading global market research company, published a research report titled, “Real-world Data (RWD) Market by source (EMR, Claims, Pharmacy, Disease Registries), Application [Market Access, Drug Development & Approvals (Oncology, Neurology), Post-market Surveillance], End User (Pharma, Payers, Providers)- Forecast to 2029”.

According to this latest publication from Meticulous Research®, the global real-world data (RWD) market is expected to grow at a CAGR of 8.2% from 2022 to 2029, to reach $2 billion by 2029. Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus on personalized healthcare have positively impacted the RWD market. However, the lack of standardized methodologies to generate RWD poses a market challenge.

Adopting AI in RWD studies is the latest trend in the RWD industry. AI integrated RWD studies can enhance data anomaly detection, standardization, and quality check at the pre-processing stage. AI-powered RWD studies can serve as a valuable tool in collecting, organizing, and analysing the increasing amount of data generated from disparate datasets. AI integrated wearable devices/sensors can automatically and continuously collect patient data, relieving the patient of this task. Together with wearable technology, AI techniques offer new approaches to developing real-time, power-efficient, mobile, and personalized patient data.

The global RWD market is segmented based on Source (EMR/EHR/Clinical Data, Claims & Billing Data, Pharmacy Data, Product/Disease Registries Data, Genomics Data, and Other Datasets), Application (Market Access & Reimbursement/Coverage Decisions, Drug Development & Approvals, Post-market Surveillance, Medical Device Development & Approvals, and Other Applications), End User (Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, and Other End Users), and Geography. The study also evaluates industry competitors and analyses their market share at the global and regional levels.

Download Free PDF Sample Copy of the Report (with COVID-19 Impact Analysis):  https://www.meticulousresearch.com/download-sample-report/cp_id=5297

Scope of the Report

RWD Market, by Source

·         EMR/EHR/Clinical Data

·         Claims & Billing Data

·         Pharmacy Data

·         Product/Disease Registries Data

·         Genomics Data

·         Other Datasets (Note – Other Datasets segment includes data generated from mobile devices, wearable devices, and social media)

RWD Market, by Application

·         Market Access & Reimbursement/Coverage Decisions

·         Drug Development & Approvals

o    Oncology

o    Neurology

o    Immunology

o    Cardiovascular Diseases

o    Other Therapeutic Areas

·         Post-market Surveillance

·         Medical Device Development & Approvals

·         Regulatory and Clinical Decision-Making (Note – Other Therapeutic Areas majorly include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases)

RWD Market, by End User

·         Pharmaceutical, Biotechnology, and Medical Device Companies

·         Healthcare Payers

·         Healthcare Providers

·         Other End Users (Note – Other end users majorly include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)

RWD Market, by Geography

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    France

o    U.K.

o    Italy

o    Spain

o    Rest of Europe (RoE)

·         Asia-Pacific (APAC)

o    Japan

o    China

o    India

o    South Korea

o    Taiwan

o    Singapore

o    Rest of APAC (RoAPAC)

·         Latin America

·         Middle East & Africa

To gain more insights into the market with a detailed table of content and figures, click here : https://www.meticulousresearch.com/product/real-world-data-market-5297

Based on source, in 2022, the EMR/EHR/clinical data segment is estimated to account for the largest market share of the RWD market owing to the significant amounts of data generated in hospitals, the increasing adoption of EHR/EMR in hospitals, and the increased use of clinical data for RWE generation. EHRs are the commonly used form of healthcare database. EHR data is vital in collecting and generating actionable information at the FDA. The federal agency is focused on making real-world data (RWD) available for clinical studies as a strategic priority and intends to issue guidance on supporting “more accessible clinical trials” through a decentralized approach. Such initiatives would propel the adoption of EHR data for real-world data generation during the forecast period.

Based on application, in 2022, the market access & reimbursement/coverage decisions segment is estimated to account for the largest market share of the RWD market. The large market share of this segment is primarily attributed to the increasing demand for real-world data to accelerate drug discovery & development and deliver a value-based price. With rising therapy costs, healthcare payers are focusing on evidence of clinical value for making decisions associated with providing coverage. RWD helps and provides a means for demonstrating value, ranging from confirming randomized trial benefits in real-world populations to a fuller characterization of resource impacts. The pharmaceutical, biotech, and medical device manufacturers use RWD derived from patient populations to analyse the clinical trial data to deliver a value-based price that appeals to more payers with increased value and provides maximum profit to the company. Payers use RWD to understand how treatments work and guide their medication coverage and reimbursement decisions.

Based on end user, in 2022, the pharmaceutical, biotechnology, and medical device companies’ segment is estimated to account for the largest market share of the RWD market. The large market share of this segment is attributed to the increasing importance of RWD in drug development & approvals, and the growing need to avoid costly drug recalls and assess drug performance in real-world settings. The healthcare landscape is developing and is shifting from volume to value-based care. Pharmaceutical companies have been looking for new ways to provide the best treatments to patients. RWD helps in understanding real-life clinical practices and actual health outcomes of drugs. Pharmaceuticals and biotechnology companies have adopted various strategies to demonstrate the value of their products, faster data collection, drive drug development, address regulatory requirements, support outcomes-based contracts, minimize the risk of product failure, and reduce products’ time to reach the market.

Request Customization Report : https://www.meticulousresearch.com/request-customization/cp_id=5297

Geographic Review:

This market research report analyses major geographies and provides a comprehensive analysis of North America (U.S., Canada), Asia-Pacific (China, Japan, India, Australia, and RoAPAC), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Latin America, and the Middle East & Africa.

Key Players

Key companies operating in the global RWD market are Anthem, Inc. (U.S.), IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).

You can Buy Report from Here : https://www.meticulousresearch.com/Checkout/62327099

Key questions answered in the report-

·  Which are the high-growth market segments in terms of source, application, end user, and regions/countries?

·  What was the historical market for real-world data (RWD) market across the globe?

·  What are the market forecasts and estimates for the period 2022–2029?

·  What are the major drivers, restraints, challenges, opportunities, and trends in the global real-world data (RWD) market?

·  Who are the major players in the global real-world data (RWD) market?

·  How is the competitive landscape, and who are the market leaders in the global real-world data (RWD) market?

·  What are the recent developments in the real-world data (RWD) market?

·  What are the different strategies adopted by the major players in the real-world data (RWD) market?

·  What are the geographical trends and high growth regions/countries?

 Contact Us: Meticulous Research® Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

[supercheapsheep]

Best escapism for me right now. @msfsofficial I flew a short 35min flight over Central Africa (Nigeria, landed at Kano) using IFR for the most part as I was in glorious, thick clouds. What's was more amazing is that due to the real world data winds, there was a dust storm that flicked the notable orange / red dust into the clouds at approx 4000-6000ft. Amazing. #microsoftflightsimulator #flightsimulator #fs #flightsim #aviation #microsoft #fsx #msfs #xplane #microsoftsurfacepro #microsoftflightsimulatorx #simulator #aviationphotography #avgeek #microsoftlumia #virtualpilot #aviationlovers #flightsimulatorx #escapism #microsoftgames #microsoftpartner #gaming #microsoftdynamics #flightsimulation #microsoftpowerpoint #pilotlife #xl #flight #microsoftai #realworlddata (at Kano, Nigeria) https://www.instagram.com/p/CEVW1gwJma5/?igshid=1o69xulme5g3u

[segmed]

What if your medical data could help save lives worldwide? Hospitals generate massive amounts of imaging data, yet more than 80% of it remains unused for research. Imagine the breakthroughs we’re missing! AI in healthcare is only as good as the data it learns from—so how can we do better? At Segmed, we’re dedicated to unlocking the full potential of Real-World Imaging Data (RWiD) to drive innovation in healthcare. By providing structured, de-identified radiology images and reports from diverse populations, we empower researchers to: ✅ Train AI models faster and more accurately ✅ Develop better medical devices with real-world data ✅ Improve patient outcomes through precision medicine ✅ Strengthen clinical trials with real-world evidence

[segmed]

💡💙What if we could detect pancreatic cancer before symptoms even appear? 💡💙 Pancreatic cancer is one of the deadliest cancers, with a 5-year survival rate of less than 12%. Why? Because it’s often diagnosed too late. Early detection is critical—but how can we make it a reality? AI-powered imaging could be the key. Recently, Segmed’s real-world imaging data was used to develop and validate AI algorithms aimed at identifying early pancreatic cancer indicators. With access to diverse, de-identified medical imaging data, innovators can: ✅ Train AI models to detect pancreatic cancer earlier ✅ Improve diagnostic accuracy and patient outcomes ✅ Accelerate research in precision medicine and drug development At Segmed, we: 🔹 Source & curate real-world imaging data 🔹 De-identify & structure data for AI & clinical research 🔹 Empower innovators to drive breakthroughs in healthcare The future of cancer detection depends on high-quality, diverse datasets. Let’s work together to advance early diagnosis. 💡 How do you see AI transforming cancer detection in the next decade? Share your insights in the comments! 👉 Want to partner with Segmed? Learn more here: https://www.segmed.ai/solutions/for-healthcare-providers

[segmed]

Segmed Joins Forces with @Bayer to Advance AI in Medical Imaging

We’re thrilled to announce a groundbreaking collaboration with Bayer to integrate Segmed’s real-world imaging data (RWiD) solution into Bayer’s AI Innovation Platform (AIIP). Together, we aim to accelerate the development of AI-powered healthcare solutions that benefit radiologists and patients alike. 💡 What does this mean? With access to 100 million diverse, de-identified imaging studies via Segmed, Bayer’s platform will empower researchers, developers, and healthcare innovators to: 🔹 Build scalable and compliant AI medical imaging tools 🔹 Tackle the growing imaging workloads faced by radiologists 🔹 Advance patient outcomes through cutting-edge solutions Dr. Martin Willemink, MD PhD FSCCT, our Co-founder and CEO, shares: "Being part of an end-to-end AI developer environment has been a key vision since we founded Segmed. Through this collaboration, we’ll help healthcare organizations efficiently tap into fit-for-purpose data, ultimately improving patient outcomes." We sincerely thank Bayer for trusting Segmed as a partner in this journey to advance innovation in medical imaging and improve patient care worldwide. This partnership combines Segmed’s expertise in de-identified imaging data with Bayer’s leadership in healthcare innovation, regulatory know-how, and clinical excellence. Together, we’re driving real impact in healthcare by reducing costs, supporting radiologists, and advancing patient care. 💻 Learn more about Segmed’s mission and our cutting-edge solutions at https://www.segmed.ai/.

[healtharkinsightss]

RWEsearch2024 | Day 1 | Talent Ecosystem in India to Serve Global Healthcare

Experts from Nagarro, THB, and Indegene highlighted India’s growing role in global healthcare at the RWEsearch Virtual Summit 2024, hosted by Healthark Insights.

🔹 Andrei Doibani, MD & Global BU Head, Nagarro – With 25+ years in tech, he drives global life sciences innovation through technology integration.

🔹 Mridul Karkara, BU Head, THB – Specializes in scaling next-gen healthcare data solutions, with expertise in strategy, growth, and M&A across the US, India, and Europe.

🔹 Marut Setia, SVP, Indegene – With 13+ years at GE Healthcare, he leads business transformation and growth across South Asia, ASEAN, China, and Japan.

[segmed]

❓💡 What if AI could detect breast cancer risk earlier than ever before? ❓💡 Early detection saves lives, but many women still face delayed diagnoses due to limited access to advanced screening tools. What if AI could change that? Recently, Segmed’s real-world imaging data was used to clinically validate an AI algorithm designed to assess breast cancer risk. This breakthrough technology could help expedite the identification of at-risk women, leading to earlier intervention and better outcomes. At Segmed, we: ✅ Source diverse, real-world imaging data from healthcare providers ✅ De-identify and structure it for research use ✅ Empower AI and healthcare innovators with high-quality datasets AI in healthcare is only as strong as the data it learns from. Let’s work together to unlock new possibilities in early disease detection. 💡 How do you see AI transforming cancer detection in the next decade? Drop your thoughts in the comments! 👉 Want to collaborate? Learn more by reaching to us out here: https://www.segmed.ai/

[segmed]

🌍✨ What if your medical data could help save lives worldwide? Hospitals generate massive amounts of imaging data, yet more than 80% of it remains unused for research. Imagine the breakthroughs we’re missing! AI in healthcare is only as good as the data it learns from—so how can we do better? At Segmed, we’re dedicated to unlocking the full potential of Real-World Imaging Data (RWiD) to drive innovation in healthcare. By providing structured, de-identified radiology images and reports from diverse populations, we empower researchers to: ✅ Train AI models faster and more accurately ✅ Develop better medical devices with real-world data ✅ Improve patient outcomes through precision medicine ✅ Strengthen clinical trials with real-world evidence 💡 How do you see AI transforming healthcare in the next five years? Drop your thoughts in the comments! 👉 Want to partner with Segmed? Learn more here: https://www.segmed.ai/contact-us

[healtharkinsightss]

RWEsearch 2024 | Day 2 | Industry Trends in Real World Data

Healthark Insights welcomed Jeffrey Morgan and Raveen Sharma from Deloitte at RWEsearch 2024.

Jeffrey Morgan, Managing Director at Deloitte, leads the ConvergeHEALTH Real World Evidence practice, driving innovation in life sciences through digital health data. Raveen Sharma, also a Managing Director, specializes in bridging data and impactful healthcare decisions.

At #RWEsearch2024, they shared key insights into emerging trends in real-world data and evidence, emphasizing the role of data-driven decision-making in shaping healthcare innovation. Their expertise provided attendees with a forward-looking perspective on the evolving healthcare landscape and the future of real-world evidence.